The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024First-in-human Phase 1a Study to Assess Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending doses of SB-0110 after Oral Administration in Healthy Subjects
Study Rationale: Although levodopa is an effective treatment for Parkinson’s disease (PD), it has a debilitating on-target side effect of dyskinesia. An optimal PD therapy would selectively activate...
-
Research Grant, 2024Determining Optimal Cognitive Measures and Clinical Trial Endpoints in Lewy Body Disorders
Study Rationale: People with Lewy body disorders, including Parkinson’s disease (PD) and dementia with Lewy bodies (DLB), often experience cognitive impairment that can impact function, independence...
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biology, 2024Alterations in DNA Repair Mechanisms in Parkinson’s Disease Neurons and their Correlation with Clinical Variables
Study Rationale: Preserving the fidelity of genetic information is essential for life. Consequently, all organisms have developed efficient systems for repairing DNA damage. One of the consequences of...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024Assessing the Safety and Efficacy of a Novel Enzyme Inhibitor in Reducing Neuroinflammation and Enhancing Neuroprotection in Parkinson’s Disease
Study Rationale: Parkinson’s disease (PD) is characterized by neuroinflammation and the loss of dopamine neurons. Recently, epoxy-fatty acids have been shown to be neuroprotective in preclinical...
-
iPSC Phenotyping Environmental Exposure Program, 2024Establishing a Proof-of-concept, Automated Platform for Studying the Interactions of Genetic and Environment-based Toxicity in Human Cell Models of Parkinson’s Disease
Study Rationale: Many studies of Parkinson’s disease (PD) focus on investigating the disease’s genetic component. Yet only about 22% of PD diagnoses carry a genetic association. Increasing evidence...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024Evaluating the Role of CK1d Inhibition in Sleep Dysregulation and Alpha-synuclein Pathology in Preclinical Models of Parkinson’s Disease
Study Rationale: Disrupted sleep is an early sign of Parkinson’s disease (PD) that worsens as the disease progresses. Chronic symptoms of PD include alternations in sleep patterns and changes in the...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.